No Data
No Data
Stem Inc, PSOL, and others [Emerging Markets Press Release]
GM0-R&AI TE HOLDINGS PTE. LTD. (Singapore) has signed a capital and business partnership agreement with stock splits of PSOL 2 shares ← 1 share and Hennge's repurchase of own shares ending. CocoPeli starts a new business. Patent registration of stem inc-recycling-induced medicine ledasemtide (HMGB1 fragment peptide) for cardiomyopathy and old myocardial infarction as indications (Australia).
Is it strong, the external environment has settled down, and push buying is dominant
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. In the US stock market on the 24th of last weekend, the Dow average rebounded slightly to 39,069.59 dollars, which was 4.33 dollars higher (+ 0.01%) for the first time in 3 days. Durable goods orders and consumer confidence indices were good, and since the expected inflation rate fell below expectations, long-term interest rates began to decline, which became a stock price support factor. Meanwhile, participants were limited ahead of the consecutive holidays, and the Dow's upper price was limited. Today's emerging markets are dominated by buying
GMO Research & AI --- Launch of “GMO Ask for New Business Development,” a research service for new business development
GMO Research & AI <3695> announced on the 14th that it has developed a package-type survey service that can easily carry out investigations using survey templates, and has started providing a research service “GMO Ask for New Business Development” for new business development as the first step. “GMO Ask for New Business Development” is a package-type research service for new business development departments and startups of operating companies. Research paper created by utilizing the company's research knowledge
GMO Research & AI: Quarterly Report - 23rd Quarter 1st Quarter (2024/01/01 - 2024/03/31)
GMO Research & AI: Confirmation
GMO ReAI -- 1Q sales to domestic business companies and overseas research companies progressed smoothly
GMO Research & AI <3695> announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 8th. Sales decreased 4.6% from the same period last year to 1,361 billion yen, operating profit fell 39.6% to 119 million yen, ordinary profit fell 36.3% to 122 million yen, and quarterly net profit attributable to parent company shareholders fell 32.1% to 92 million yen. Regarding sales by sales channel, sales to domestic operating companies increased 57.2% from the same period last year to 191 million yen
No Data